EC approves Eurneffy (adrenaline) 1mg for the emergency treatment of anaphylaxis in children aged 4 years and older (≥15 kg) – ALK

ALK announced that children aged 4 and older living with severe allergies across the EU can now access the first and only needle-free adrenaline treatment for anaphylaxis, after the European Commission (EC) granted marketing authorisation for Eurneffy  1 mg – extending a class of treatment previously available only by injection.

Eurneffy    1 mg is now indicated for the emergency treatment of anaphylaxis due to insect stings or bites, foods, medicinal products and other allergens, as well as idiopathic or exercise-induced anaphylaxis in children aged 4 years and older with a bodyweight between 15 kg and 30 kg. This approval extends the existing marketing authorisation for Eurneffy  2 mg, granted by the EC in August 2024 for the emergency treatment of anaphylaxis in adults and children weighing ≥30 kg.

Anaphylaxis – the most severe, life‑threatening form of allergic reaction requiring immediate intervention – affects an estimated 1 to 761 out of every 100,000 children in Europe each year, with food allergies responsible for more than two‑thirds of cases.
This approval means more people with severe allergies including children aged 4 years and older (≥15 kg) will be eligible for treatment with Eurneffy , the only needle-free adrenaline-based product currently approved across the EU.

“This approval reflects our continued commitment to expanding treatment options for children with severe allergies.For decades, children at risk of anaphylaxishave been limited to injectable adrenaline – yet fear of needles, hesitancy to act and incorrect administration mean adrenaline is too often not carried or used in time. Eurneffy  1 mg aims to address these barriers, offering an efficacious, needle-free, user-friendly adrenaline solution with the potential to transform the lives of those living with, or caring for, children with severe allergies. This approval brings us closer to ensuring every family affected by severe allergies has a treatment they will actually carry and use.” – Flora Beiche-Scholz, EVP Commercial Operations Europe, ALK

Clinical evidence and safety profile

·        Eurneffy  provides rapid absorption of adrenaline within minutes of administration.

·        Eurneffy  has an established safety profile, based on clinical data from the Eurneffy  development programme involving over 700 participants.

·        The most common adverse reactions in subjects weighing 15 kg to less than 30 kg treated with Eurneffy  1 mg included: nasal congestion (19.0%), upper respiratory tract congestion (14.3%), dry throat, nasal dryness, and paraesthesia (each 9.5%).

·        There were no clinically relevant differences in the safety between the paediatric and adult populations treated with Eurneffy .

·        Eurneffy  2 mg performed as well as traditional adrenaline auto-injectors or intramuscular adrenaline across a range of real-world scenarios examining the clinical pharmacological effect including single and repeat doses, self-administration, and situations with nasal congestion from allergies.

·        Eurneffy  1 mg dose demonstrated a comparable absorption and pharmacodynamic effect in children (15-30 kg) as the 2 mg dose in children and adults above 30 kg.

This approval applies to all 27 European Union (EU) member states, Iceland, Norway and Liechtenstein.